Free Trial

PharmaCyte Biotech (PMCB) Stock Price, News & Analysis

+0.01 (+0.47%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
6,672 shs
Average Volume
6,963 shs
Market Capitalization
$18.08 million
P/E Ratio
Dividend Yield
Price Target
PMCB stock logo

About PharmaCyte Biotech Stock (NASDAQ:PMCB)

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

PMCB Stock Price History

PMCB Stock News Headlines

MyMD Pharmaceuticals Secures Strategic Investments
PharmaCyte Biotech Inc PMCB
PharmaCyte Biotech Invests In Femasys - Quick Facts
Los Angeles Biotech News
Biotech ETFs’ Performance Deserves A Look
PharmaCyte to evaluate opportunities; CEO steps down
See More Headlines
Receive PMCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$4.33 per share


Free Float
Market Cap
$18.08 million
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Joshua N. Silverman (Age 54)
    Interim CEO, President & Director
    Comp: $197.92k
  • Mr. Carlos A. Trujillo CPA (Age 66)
    CPA, Chief Financial Officer
    Comp: $380k
  • Dr. Jose L. Iglesias M.D. (Age 67)
    Consulting Chief Medical Officer
  • Dr. Hans-Peter Hammes
    Member of Medical & Scientific Advisory Board and Consultant

PMCB Stock Analysis - Frequently Asked Questions

How have PMCB shares performed in 2024?

PharmaCyte Biotech's stock was trading at $2.16 at the beginning of 2024. Since then, PMCB shares have decreased by 0.9% and is now trading at $2.14.
View the best growth stocks for 2024 here

When is PharmaCyte Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024.
View our PMCB earnings forecast

How were PharmaCyte Biotech's earnings last quarter?

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) issued its earnings results on Monday, March, 18th. The company reported ($0.65) earnings per share (EPS) for the quarter.

Who are PharmaCyte Biotech's major shareholders?

PharmaCyte Biotech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include K2 Principal Fund L.P. (3.88%).

How do I buy shares of PharmaCyte Biotech?

Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PMCB) was last updated on 5/24/2024 by Staff

From Our Partners